News for Enlivex Therapeutics Ltd. (ENLV.TA)

Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis, have completed a follow-up period of at least three months, the trial’s primary timepoint for measurement of key endpoints. The data are being analyzed and audited, with a target date of August 18, 2025 for the public release of audited topline results for three-month key endpoints, including safety and change from baseline in knee pain and function.

On July 22, 2025, Enlivex Therapeutics (ENLV) received continued support from the investment research firm D. Boral Capital. Analyst Jason Kolbert has decided t

Enlivex Therapeutics (ENLV) has announced its participation at the European Congress of Rheumatology, scheduled for June 11-14, 2025, in Barcelona, Spain. The c

Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( ENLV, the ”œCompany”), a clinical-stage macrophage reprogramming immunoth

Presentations to underscore AllocetraTM's novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) --

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( ENLV, the ”œCompany”), a clinical-stage macrophage reprogramming immunot

**media[584961]**

Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( ENLV, the ”œCompany”), a clinical-stage macrophage reprogramming immunot

Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( ENLV, the ”œCompany”), a clinical-stage macrophage reprogramming immunot

**media[555557]**

Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the ”œCompany”), a clinical-stage macrophage reprog

Significant Stock Acquisition by ARMISTICE CAPITAL, LLC (Trades, Portfolio) On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a strategi

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, I

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( ENLV, the ”œCompany”), a clinical-stage macrophage reprogramming immunoth

**media[482172]**

Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( ENLV, the ”œCompany”), a clinical-stage macrophage reprogramming immunothe

Enlivex stock hits 52-week low at $1.15 amid market challenges

Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...